Importantly, the loss of SMARCA4 was found to be synthetic lethal with the inhibition of cyclin-dependent kinase 4/6 or aurora kinase A, highlighting their inhibitors as potential therapeutic agents in SMARCA4-deficient NSCLC cases [25, 26]. Here, CDK4 is linked to non-small cell lung carcinoma.